MYC and familial pancreatic carcinoma: Regarding the poor response of pancreatic cancer to current chemotherapy protocols, the prevalence of c-Myc deregulation in pancreatic cancer, and the promising results of preclinical studies, it is worth investigating the effect of different inhibitors of c-Myc in clinical trials of pancreatic cancer.